Asia Pacific Custom Antibody Services Market

Asia Pacific Custom Antibody Services Market Outlook

The Food and Drug Administration (FDA) approves biosimilar products and provides the scientific and regulatory advice needed to introduce safe and effective biosimilars to the market. The approval of biosimilar products can improve patient care by increasing the number of medication options at potentially lower costs.

A few recent approvals of biosimilar products are mentioned below:

Biosimilars can reduce treatment costs and improve patient access to biologic therapies. In recent years, a vast range of biosimilars have been approved by the FDA. According to ScienceDirect.com, biosimilars can retain costs and expand the availability of monoclonal antibodies. Thus, the rising approvals of biosimilars fuel the growth of the custom antibody services market.

Asia Pacific Custom Antibody Services Market Country Insights

Based on country, the Asia Pacific custom antibody services market comprises Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific. China held the largest share in 2023.

China is home to various medical, pharmaceutical, and biotechnology companies operating across the world. It has over ~300 medical contract research organizations (CROs) along with prominent biopharmaceutical product manufacturers. CROs utilize custom antibody services to develop highly specific antibodies for research and drug development. Custom antibodies help CROs provide precise and effective solutions for customer's specific research needs. In 2020, Bio-Thera Solutions (a Chinese biotech company) received US$ 241 million in funding from investors, including the China Life Science Fund, to support the development of its monoclonal antibodies pipeline. These antibodies are widely utilized in various applications, including drug discovery, diagnostics, and therapeutics. In March 2024, Sino Biological, Inc., which provides biological research reagents and contract research services, formed a services partnership with Toronto-based Rapid Novor, Inc. Under the agreement terms, Sino Biological would market Rapid Novor's proprietary de novo REmAb monoclonal antibody sequencing service in combination with its custom monoclonal antibody development and production services. Thus, an upsurge in funding initiatives from governments and investors, and strategic efforts by companies hold potential growth opportunities for the custom antibody services market in China.

Asia Pacific Custom Antibody Services Market Company Profiles

Some of the key players operating in the market include Thermo Fisher Scientific Inc; Sino Biological Inc.; GenScript Biotech Corporation; Biochain Incorporated; R&D Systems, Inc; Kaneka Eurogentec S.A.; Fortis Life Sciences; Precision Antibody (A&G Pharmaceutical, Inc.; Biocytogen Pharmaceuticals Beijing Co Ltd; Abgenex; Creative Biolabs Inc; Agilent Technologies Inc; Bioklone; and Scantibodies Laboratory, Inc. among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Asia Pacific Custom Antibody Services Market Research Methodology :

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.
• Industry trade journals and other relevant publications.
• Government documents, statistical databases, and market reports.
• News articles, press releases, and webcasts specific to companies operating in the market.

Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

• Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.
• Enhance the expertise and market understanding of the analysis team.
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise